Form 4: Pulmonx Director Glendon E. French III Receives Significant RSU Grant

Pulmonx Corporation's Director, Glendon E. French III, was granted 37,153 Restricted Stock Units, increasing his beneficial ownership to over 1 million shares.

Summary

• Glendon E. French III, a Director of Pulmonx Corporation (LUNG), was granted 37,153 shares of common stock in the form of Restricted Stock Units (RSUs).
• The RSUs were granted on June 2, 2025, at a price of $0 per share, indicating a compensation grant.
• Following this transaction, Mr. French's direct beneficial ownership in Pulmonx Corporation increased to 1,029,127 shares.
• These RSUs are set to vest on the earlier of the one-year anniversary of the grant date (June 2, 2026, or the next business day) or the date of the Annual Meeting of Stockholders for the year subsequent to the grant date.

Sentiment

Score: 7

Explanation: The grant of RSUs to a director is a positive sign of continued alignment between management/board and shareholder interests, and a standard compensation practice. It's not a major market moving event but indicates stability and retention.

Positives

• The grant of 37,153 Restricted Stock Units to Director Glendon E. French III aligns his interests with long-term shareholder value.
• The increase in beneficial ownership to 1,029,127 shares demonstrates continued commitment from a key director.

Future Outlook

The RSU grant includes future vesting conditions, indicating a forward-looking compensation structure designed to retain and incentivize the director over the coming year.

Industry Context

This RSU grant is a standard form of equity compensation for directors in the medical device or biotechnology industry, aiming to align executive and director interests with long-term company performance and shareholder returns.

Related Party Transactions

• The RSU grant to Director Glendon E. French III can be considered a related party transaction as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's interests with shareholders by tying compensation to future stock performance.
• Employees: No direct impact on general employees.

Next Steps

• The granted Restricted Stock Units will vest on the earlier of June 2, 2026 (or the next business day) or the date of the Annual Meeting of Stockholders for the year subsequent to the grant date.

Key Dates

Keywords

Pulmonx Corporation, LUNG, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU Grant, Director Compensation, Equity Grant, Beneficial Ownership